Acumen Pharmaceuticals (ABOS) EBITDA (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of EBITDA data on file, last reported at -$21.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 30.36% year-over-year to -$21.1 million; the trailing twelve-month figure through Mar 2026 stood at -$114.6 million (up 9.48% YoY), and the FY2025 full-year result was -$123.8 million, down 8.61% from the prior year.
• EBITDA climbed to -$21.1 million in Q1 2026, from -$25.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$9.2 million in Q1 2022 to a low of -$41.8 million in Q2 2025.
• A 5-year average of -$21.5 million and a median of -$18.5 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 202.56% in 2022 and soared 36.36% in 2025, its largest moves.
• Tracing ABOS's EBITDA over 5 years: stood at -$14.2 million in 2022, then fell by 29.74% to -$18.5 million in 2023, then tumbled by 114.2% to -$39.6 million in 2024, then soared by 36.36% to -$25.2 million in 2025, then rose by 16.07% to -$21.1 million in 2026.
• Business Quant data shows ABOS's EBITDA at -$21.1 million in Q1 2026, -$25.2 million in Q4 2025, and -$26.5 million in Q3 2025.